Check whether PD-1 treatment helps esophagus cancer before surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell cancer in the middle or upper chest esophagus that is stage T1–4a with lymph node spread (N1–3), or T3–4a with no lymph node spread (N0), and it can likely be removed with surgery
- You have never had any cancer treatment before starting this study
- You are expected to live more than 6 months, and you are age 18 to 70
- Your blood counts and liver/kidney tests are in acceptable ranges, and your energy level score (WHO PS) is 0–1
- You must be able to have the planned surgery and be willing to sign the consent form
- You cannot be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This study uses an “immune indicator model” to help predict how well a PD-1 antibody (a cancer-fighting immune drug) works when combined with chemotherapy for stage IV esophageal squamous cell cancer. If you qualify, you receive the treatment and the researchers also look for immune-related signs that may explain who benefits most.
This trial tests a combination of immunotherapy (sintilimab) and chemotherapy given before surgery for esophageal cancer that can be surgically removed. The goal is to see if this approach helps shrink tumors and improve outcomes.
This Phase 3 trial studies whether adding sintilimab (an immunotherapy medicine) after surgery improves outcomes for people with locally advanced esophageal squamous cell carcinoma. It compares sintilimab plus a chemo/RT plan versus the same chemo/RT plan without immunotherapy.
This trial tests whether giving the immunotherapy drug sintilimab together with standard chemotherapy and a growth factor injection before surgery can help people with a certain type of esophageal cancer (squamous cell carcinoma) that is still removable. The goal is to improve treatment outcomes before the operation.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.